Galapagos announces capital increase
(Thomson Reuters ONE) -
Mechelen, Belgium; 19 May 2015 - Galapagos NV (Euronext & NASDAQ: GLPG)
announced today a capital increase in connection with the closing of its global
offering.
As of today, Galapagos' total share capital amounts to ?207,747,029.16; the
total number of securities conferring voting rights is 38,403,176, which is also
the total number of voting rights (the "denominator"), and all securities
conferring voting rights and all voting rights are of the same category. The
total number of rights (warrants) to subscribe to not yet issued securities
conferring voting rights is 3,011,805, which equals the total number of voting
rights that may result from the exercise of these warrants (but excludes the
625,740 warrants of Warrant Plan 2015 which were created on 30 April 2015,
subject to acceptances). Galapagos does not have any convertible bonds or
shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other indications. In
the field of inflammation, AbbVie and Galapagos signed a collaboration agreement
for the development and commercialization of filgotinib. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in Phase 2B
studies in RA and in Phase 2 in Crohn's disease. Galapagos reported good
activity and a favorable safety profile at 12 weeks in both the DARWIN 1 and 2
trials in RA. AbbVie and Galapagos also signed a collaboration agreement in
cystic fibrosis to develop and commercialize molecules that address mutations in
the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and
corrector GLPG2222 is at the pre-clinical candidate stage. GLPG1205, a first-
in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently being
tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients.
GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown
favorable safety in a Phase 1 trial and is expected to enter Phase 2 in
idiopathic pulmonary fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia.
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir(at)glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but are not always,
made through the use of words or phrases such as "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," "continues," "we believe," "we intend," as well as similar
expressions. Such forward-looking statements may involve known and unknown
risks, uncertainties and other factors which might cause the actual results,
financial condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future results,
financial conditions, performance or achievements expressed or implied by such
forward-looking statements. Among the factors that may result in differences
are the inherent uncertainties associated with competitive developments,
clinical trial and product development activities, regulatory approval
requirements and estimating the commercial potential of our product candidates.
A further list and description of these risks, uncertainties and other risks can
be found in the company's Securities and Exchange Commission filing and reports,
including in the company's prospectus filed with the SEC on May 14, 2015 and
future filings and reports by the company. Given these uncertainties, the reader
is advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication of
this document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
regulation.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1922649]
Unternehmensinformation / Kurzprofil:
Datum: 19.05.2015 - 22:01 Uhr
Sprache: Deutsch
News-ID 394492
Anzahl Zeichen: 5767
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 166 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos announces capital increase"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
